ArticleDiagnostic and interventional radiology (Ankara, Turkey)2026
Abbreviated liver magnetic resonance imaging with a second-shot arterial phase image to assess the viability of treated hepatocellular carcinoma after non-radiation locoregional therapy.
Article in Diagnostic and interventional radiology (Ankara, Turkey), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the feasibility of abbreviated liver magnetic resonance imaging (AMRI) with a second-shot arterial phase (SSAP) image for the viability of treated hepatocellular carcinoma (HCC) after non-radiation locoregional therapy (LRT).
methodsWe retrospectively enrolled patients with non-radiation LRT for HCC who underwent the modified gadoxetic acid-enhanced liver MRI protocol, which includes routine dynamic and SSAP imaging after the first and second injection of gadoxetic acid, respectively (6 mL and 4 mL, respectively), and an available reference standard for tumor viability in the treated HCC between March 2021 and February 2022. Two radiologists independently reviewed the full-protocol MRI (FP-MRI) and AMRI with SSAP. For the FP-MRI, observations were assigned using the Liver Imaging Reporting and Data System treatment response (LR-TR) algorithm v.2024. In the AMRI with SSAP, the observations were assigned using the abbreviated LR-TR category according to the arterial mass-like enhancement in SSAP. Ancillary features, such as diffusion restriction and T2-weighted mild-to-moderate hyperintensity, were also optionally used.
resultsOf the 95 patients (70 men and 25 women; mean age, 68.7 years), 42 (44.2%) had viable lesions and 53 (55.8%) had non-viable lesions. The scan time of the simulated AMRI was significantly shorter than the FP-MRI (7.6±0.49 and 23.6±0.50 min, respectively; p<0.001). For evaluating the viability of treated HCC, there were no significant differences in the sensitivity and specificity between the FP-MRI and AMRI with SSAP (sensitivity, 85.7% vs. 80.1%,
conclusionThe abbreviated LR-TR score in AMRI with SSAP showed non-inferior diagnostic performance to FP-MRI in terms of evaluating the viability for the treated HCC, which may be helpful in clinical practice alongside a decreased scan time. CLINICAL SIGNIFICANCE: Abbreviated liver MRI with SSAP may be helpful for evaluating the viability of treated HCC in practice, while also providing a decreased scan time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.